Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Sep 18, 2020; 11(9): 400-410
Published online Sep 18, 2020. doi: 10.5312/wjo.v11.i9.400
Published online Sep 18, 2020. doi: 10.5312/wjo.v11.i9.400
Factors predisposing to thrombosis after major joint arthroplasty
Zoe H Dailiana, Nikolaos Stefanou, Sokratis Varitimids, Nikolaos Rigopoulos, Apostolos Dimitroulias, Theofilos Karachalios, Konstantinos N Malizos, Department of Orthopaedic Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa 41500, Greece
Despoina Kyriakou, Laboratory of Haematology - Transfusion Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa 41500, Greece
Panagoula Kollia, Department of Human Genetics, Faculty of Biology, National and Kapodistrian University of Athens, Athens 11635, Greece
Author contributions: Dailiana ZH participated in the conception and design of the study, analysis and interpretation of the data, and drafting and critical revision of the article; Stefanou N participated in interpretation of the data and drafting of the article; Varitimids S participated in design of the study and was involved with data collection and analysis and interpretation of data; Rigopoulos N assisted in data collection, assembly and analysis; Dimitroulias A assisted in data collection, assembly and analysis; Karachalios T was involved with data collection; Malizos KN participated in the analysis and interpretation of the data and critical revision of the article; Kyriakou D was involved with data collection, analysis and interpretation; Kollia P participated in the conception and design of the study, analysis and interpretation of the data, and critical revision of the article; All authors read and approved the final manuscript.
Supported by Hellenic Association of Orthopaedic Surgery and Traumatology , No. EEXOT 20022007 .
Institutional review board statement: The study was approved by the hospital ethics committee.
Informed consent statement: All study participants, or their legal guardian, provided informed consent prior to study enrollment.
Conflict-of-interest statement: The authors of this manuscript have no conflicts of interest to disclose.
Data sharing statement: There is no additional data available.
STROBE statement: The guidelines of the STROBE Statement have been adopted in the present manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Zoe H Dailiana, MD, PhD, Professor, Surgeon, Department of Orthopaedic Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, 3 Panepistimiou Street, Biopolis, Larissa 41500, Greece. dailiana@med.uth.gr
Received: June 18, 2020
Peer-review started: June 18, 2020
First decision: July 2, 2020
Revised: July 16, 2020
Accepted: August 1, 2020
Article in press: August 1, 2020
Published online: September 18, 2020
Peer-review started: June 18, 2020
First decision: July 2, 2020
Revised: July 16, 2020
Accepted: August 1, 2020
Article in press: August 1, 2020
Published online: September 18, 2020
Core Tip
Core Tip: This prospective study evaluated the impact of genetic profiles of patients and pharmacologic factors on the development of thrombosis after lower limb arthroplasty. Thrombosis was related to the development of anti-platelet factor 4 (anti-PF4)/heparin antibodies and was correlated significantly to factor II and V mutations. Thus, screening of coagulation profile preoperatively could minimize the risk of post-arthroplasty thrombosis. Platelet monitoring does not uncover all cases of anti-PF4/heparin antibody formation, while antibody monitoring postanticoagulant administration is probably unnecessary. Fondaparinux can lead to the formation of anti-PF4/heparin antibodies and may cause heparin-induced thrombocytopenia.